Psychedelic Research

A systematic review of eight randomized trials finds MDMA-AT reduced psychopathology more than controls, but with high variability and poor harm reporting.

A randomized trial gave healthy adults LSD or placebo, then tested their learning the next day — here’s what the brain-plasticity data actually showed.

The first volunteer at Imperial College to inhale synthetic DMT returned saying he’d “seen every future where I relapse—and every one where I don’t.” Four months later his urine was still clean, the…

Strip naked, step into a coffin-size box, and let a thousand pounds of Epsom salt hold you like an invisible mattress. Kill the lights, match the water to skin temperature, and the world begins to…

A single 15-minute trip can outperform methadone on paper. When researchers pooled every published trial of N,N-dimethyltryptamine (DMT) against alcohol, opioids, cocaine, or nicotine, the average…

A 2026 preprint surveys more than 25 disciplines that generate altered states of consciousness (ASC), clustering them into five groups and identifying shared brain mechanisms. It shows that the…

A new documentary follows musician East Forest’s 16-year project of music for structured experiences — and what brain science may suggest about sound.

Preprint buzz says psilocybin fights “inflammaging.” We dug into the actual data on mushrooms, microglia, and the aging mind—and where the hype rockets past the evidence.

A systematic review finds that low‐dose psychedelics may feel like a boost for adult ADHD, but controlled trials show no drug‐specific benefit.

Meta-analysis claims DMT cuts drug use—but only when therapy is in the room. What the numbers actually say, and why the hype still outruns the data.